Results 101 to 110 of about 346 (112)

Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin

European Journal of Pharmacology, 2023
Simone Melander, Kim Henriksen
exaly  

Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss

European Journal of Pharmacology, 2023
Anna Thorsø Larsen, Kim Henriksen
exaly  

Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss

Biomedicine and Pharmacotherapy, 2023
Kim Henriksen
exaly  

KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration

European Journal of Pharmacology, 2015
Morten Asser Karsdal, Kim Henriksen
exaly  

Dose Frequency Optimization of the Dual Amylin and Calcitonin Receptor Agonist KBP-088: Long-Lasting Improvement in Food Preference and Body Weight Loss

Journal of Pharmacology and Experimental Therapeutics, 2020
Anna Thorsø Larsen, Kim Henriksen
exaly  

Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog

American Journal of Physiology - Endocrinology and Metabolism, 2017
Morten Asser Karsdal, Lars I Hellgren, Kim Henriksen   +2 more
exaly  

Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models

Biomedicine and Pharmacotherapy, 2022
exaly  

A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats

American Journal of Physiology - Endocrinology and Metabolism, 2014
Morten Asser Karsdal, Jan Erik Henriksen, Henning Beck-Nielsen   +2 more
exaly  

Dynamic programming of flights based on stochastic demands

2015
Pau Fonseca i Casas, Josep Casanovas
exaly  

The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes

American Journal of Physiology - Endocrinology and Metabolism
Anna Thorsø Larsen, Simone Melander
exaly